Stockscreener 앱 받기
2.29
1.29%
-0.03
전일 마감가:
$2.32
열려 있는:
$2.32
하루 거래량:
24,424
Relative Volume:
1.59
시가총액:
$10.13M
수익:
$20,000
순이익/손실:
$-11.06M
주가수익비율:
-0.8049
EPS:
-2.8449
순현금흐름:
$-10.53M
1주 성능:
-4.58%
1개월 성능:
-12.60%
6개월 성능:
-4.58%
1년 성능:
-9.84%
1일 변동 폭
$2.24
$2.37
1주일 범위
$2.24
$2.41
52주 변동 폭
$1.7645
$2.91
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
858-224-9600
주소
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.29 | 10.13M | 20,000 | -11.06M | -10.53M | -2.8449 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent RangeMoney Flow Index - https://www.dars.gov.et/
Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent RangeStock News - https://www.dars.gov.et/
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - kalkine.ca
Kiora Pharmaceuticals Inc (NYSE: KPRX) Stock Price, News & Analysis - Kalkine
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue ProfileFinancial Health Score - dars.gov.et
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue Profile - www.dars.gov.et
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue ProfileEarnings Cycle Outlook - www.dars.gov.et
New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com Canada
Kiora Pharmaceuticals names Keith Lane clinical development head - Investing.com
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com India
Kiora hires an executive who oversaw more than 60 eye-drug trials - Stock Titan
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com Nigeria
KPRX 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
KPRX Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Still Slips 1.5%Earnings Miss Streak - dars.gov.et
KPRX Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Still Slips 1.5%Trough Earnings Signal - dars.gov.et
Chong Kun Dang Wins Korean Rights to Kiora Retinal Drug - Seoul Economic Daily
Kiora licenses KIO-301 rights in South Korea - grafa.com
Kiora Licenses South Korean KIO-301 Rights for $1M Upfront - Minichart
Kiora PharmaceuticalsEligible for Double D - Moomoo
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Kiora Licenses KIO-301 Rights in South Korea - TipRanks
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Australia
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Australia
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com UK
Kiora Pharmaceuticals Licenses KIO-301 South Korea Rights to Chong Kun Dang for $1 Million Upfront Plus Milestones and Royalties - kalkine.ca
10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301 - Stock Titan
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - Kalkine
Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus
ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan
Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesReturn On Capital - Vinanet
Kiora Pharmaceuticals (KPRX) Rises 1.55% as Biotech Stock Holds Key Support at $2.49Regression Channel - dars.gov.et
Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Canada
Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kiora Pharmaceuticals Reports Q2 2026 Results, Advances KIO-301 and KIO-104 Trials With Runway Into Late 2028 - kalkine.ca
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceOBV Divergence - dars.gov.et
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga España
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KPRX|Kiora Pharmaceuticals Inc|Price:2.530|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.09%
0.72%
자본화:
|
볼륨(24시간):